Astrazeneca Ab

Astrazeneca Aktiebolag

Dainippon Sumitomo Pharma Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Ian Millichip

Roger Victor Bonnert

Stephen Brough

Yoshiaki Isobe

Kazuki Hashimoto

Ayumu Kurimoto

Hiroki Wada

Thomas Mcinally

Stephen Thom

Stephen Connolly

David R Cheshire

Thomas McInally

Timothy Jon Luker

Antonio Mete

Garry Pairaudeau

Anil Patel

Rukhsana Rasul

Rhonan Lee Ford

David Cox

Andrew Mather

Andrew Davies

Andrew Davis

The present invention provides an 8-oxoadenine compound having immunomodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Zrepresents alkylene, Xrepresents oxygen atom, sulfur atom, SO, NR, CO, CONR, NRCO and the like, Y, Yand Yrepresent independently a single bond or an alkylene group, Xrepresents oxygen atom, sulfur atom, NR(Ris hydrogen atom or an alkyl group) or a single bond, Rrepresents a substituted or unsubstituted alkyl group, Rrepresents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group]or its pharmaceutically acceptable salt.

9-substituted 8-oxoadenine compound

The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Zrepresents alkylene, Xrepresents oxygen atom, sulfur atom, SO, NR, CO, CONR, NRCO and the like, Y, Yand Yrepresent independently a single bond or an alkylene group, Xrepresents oxygen atom, sulfur atom, NR(Ris hydrogen atom or an alkyl group) or a single bond, Rrepresents a substituted or unsubstituted alkyl group, Rrepresents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group]or its pharmaceutically acceptable salt.

The present invention provides compounds of formula (I) in which y, m, n, R, Rand Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

Substituted 1-cyanoethylheterocyclylcarboxamide compounds

The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation. 

Compounds

There is disclosed the use of a compound of formula (I), wherein R, R, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial. Certain novel compounds of formula (Ia) and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof are disclosed; together with processes for their preparation, compositions containing them and their use in therapy. The compounds of formulae (I) and (Ia) are inhibitors of the enzyme nitric oxide synthase and are thereby particularly useful in the treatment or prohylaxis of inflammatory disease

Use of phenylheteroalkylamine derivatives

Growing community of inventors

Leicestershire, United Kingdom

Ian Millichip